Can a pill slow brain aging in Alzheimer's? early trial seeks answers
NCT ID NCT05040321
Summary
This small, early-stage study is testing whether an oral supplement called MIB-626 can reach the brain and affect biological pathways related to aging in people with mild Alzheimer's disease. Researchers will measure the supplement's levels in spinal fluid and brain scans in 22 participants over 90 days. The main goal is to see if the compound gets into the brain and activates its intended target, which could inform the design of larger future trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115-0000, United States
Conditions
Explore the condition pages connected to this study.